Recombinant hemagglutinin influenza vaccine provides broader spectrum protection

Expert Review of Vaccines

Volumn 15, Issue 8, 2016, Pages 957-966

  Dunkle, Lisa M ^a   Izikson, Ruvim ^a  

^a Protein Sciences Corp   (United States)

Author keywords

Flublok ; High dose influenza vaccine; Influenza vaccines; Quadrivalent influenza vaccine; Recombinant protein vaccines

Indexed keywords

INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; RECOMBINANT VACCINE;

ANTIGENICITY; ARTHRALGIA; ARTICLE; BINDING AFFINITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEVER; FLU LIKE SYNDROME; HEADACHE; HEALTH CARE NEED; HUMAN; INFLUENZA; INFLUENZA VACCINATION; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; MYALGIA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN;

HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; VACCINES, SYNTHETIC;

EID: 84976875142     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1080/14760584.2016.1203261     Document Type: Article

References (38)

1. E.Milián, A.A.Kamen Current and emerging cell culture manufacturing technologies for influenza vaccines. Biomed Res Int. 2015;2015:1–11.
2. M.M.J.Cox, Y.Hashimoto. A fast track influenza virus vaccine produced in insect cells. J Invert Pathol. 2011;107:S31–S41.
3. T.A.Kost, J.P.Condreay, D.L.Jarvis. Baculovirus as versatile vectors for protein expression in insect and mammalian cells. Nat Biotechnol. 2005;23:567–575.
4. K.Wang, K.M.Holtz, K.Anderson, et al. Expression and purification of an influenza hemagglutinin – one step closer to a recombinant protein-based influenza vaccine. Vaccine. 2006;24:2176–2185.
5. L.M.Dunkle, R.Izikson, P.A.Patriarca, et al. Clinical efficacy of quadrivalent recombinant influenza (Flu) vaccine vs. quadrivalent inactivated influenza vaccine (IIV) in adults 50 years of age and older – abstract I-299a. Abstracts: 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); 2015 Sept 17–22; San Diego, CA; Washington (DC): American Society of Microbiology.
6. M.M.J.Cox, L.M.Dunkle, K.Goldenthal, et al. Efficacy of recombinant influenza vaccine (Flublok Quadrivalent, RIVr) versus egg-derived inactivated vaccine4 (IIV4) in adults 50 years of age and older during a season characterized by antigenic mismatch between circulating and vaccine H3N2 strains. 19th Annual Conference on Vaccine Research – Abstract S4; 2016 Apr 18–20; Baltimore, ML; Bethesda (MD): National Foundation for Infectious Diseases.
7. D.M.Skowronski, N.Z.Janjua, G.De Serres, et al. Low 2012–2013 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLos One. 2014;9(3):e92153.• Describes the mutations in influenza virus hemagglutinin induced by adaptation to growth in eggs that result in reduced vaccine effectiveness.
8. J.J.Treanor, H.M.El Sahly, J.King, et al. Protective efficacy of a trivalent recombinant heagglutinin protein vaccine (FluBlok) against culture-confirmed influenza in healthy adults: a randomized, placebo-controlled trial. Vaccine. 2011;29:7733–7739.•• Pivotal placebo-controlled trial of Flublok in adults 18–49 years of age demonstrating clinical efficacy and, especially, efficacy against antigenically mismatched influenza strains.
9. M.M.J.Cox, D.K.Anderson Production of a novel influenza vaccine using insect cells: protection against drifted strains. Influen Other Resp Viruses. 2007;1:35–40.
10. N.Z.Janjua, D.M.Skowronski, G.De Serres, et al. Estimates of influenza vaccine effectiveness for 2007–2008 from Canada’s Sentinel Surveillance System: cross-protection against major and minor variants. J Infect Dis. 2012;205:1858–1868.
11. R.Baxter, P.A.Patriarca, K.Ensor, et al. Evaluation of the safety, reactogenicity and immunogenicity of FluBlok trivalent recombinant baculovirus-expressed hemagglutinin influenza vaccine administered intramuscularly to healthy adults 50–64 years of age. Vaccine. 2011;29:2272–2278.• Safety and immunogenicity of Flublok in adults 50–64 years of age.
12. W.A.Keitel, J.J.Treanor, H.M.El Sahly, et al. Comparative immunogenicity of recombinant influenza hemagglutinin (rHA) and trivalent inactivated vaccines (TIV) among persons ≥65 years old. Vaccine. 2010;28:379–385.• Safety and immunogenicity of Flublok in adults 65 years of age and older.
13. A.Safdar, M.A.Rodriguez, L.E.Fayad, et al. Dose-related safety and immunogenicity of baculovirus-expressed trivalent influenza vaccine: a double-blind, controlled trial in adult patients with non-Hodgkin’s B-cell lymphoma. J Infect Dis. 2006;194:1394–1397.
14. D.C.Powers, G.E.Smith, E.L.Anderson, et al. Influenza A virus vaccines containing purified recombinant H3 hemagglutinin are well-tolerated and induce protective immune responses in healthy adults. J Infect Dis. 1995;171:1595–1599.
15. G.D.Appiah, L.Blanton, T.D’Mello, et al. Influenza activity – United States, 2014–15 season and composition of the 2015–16 influenza vaccine. Morbid Mortal Wkly Rep. 2015;64:583–590.
16. B.Flannery, J.Clippard. End-of-season influenza vaccine effectiveness estimates for the 2014–15 season: US Influenza Vaccine Effectiveness (Flu VE) Network. Advisory Committee on Immunization Practices [Online]; 2015 Jun 24 [cited 2015 Sep 8]. Available from: http://www.cdc.gov/vaccines/acip/meetings/downloads/slides-2015-06/flu-02-flannery.pdf.• Estimated effectiveness of influenza vaccines during 2014–2015 in the USA.
17. H.Fineberg. Pandemic preparedness and response – lessons from the H1N1 influenza of 2009. N Engl J Med. 2014;370:1335–1342.
18. S.Shrestha, D.Swerdlow, R.Borse, et al. Estimating the burden of 2009 pandemic influenza A (H1N1) in the United States (April 2009–April 2010). Clin Infect Dis. 2011;52:S75–S82.
19. President’s Council of Advisors on Science and Technology. Report to the President on U.S. Preparations for 2009-H1N1 influenza pandemic. Washington, DC: s.n.; 2009.
20. WHO. Pandemic influenza vaccine manufacturing process and timeline. World Health Organization [Online]; 2016 [cited 2016 Mar 28] Available from: http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090806/en/.
21. R.Wagner, H.Geyer, R.Geyer, et al. N-acetyl-B-glucosaminidase accounts for differences in glycosylation of influenza virus nemagglutinin expressed in insect cells from a baculovirus vector. J Virol. 1996;70:4103–4109.
22. J.-R.Chen, Y.-H.Yu, Y.-C.Tseng, et al. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci USA. 2014;111:2476–2481.
23. K.M.Holtz, D.K.Anderson, M.M.Cox Production of a recombinant influenza vaccine using the baculovirus expression vector system. BioProcess J. 2003;2:65–73.
24. S.Yoden, H.Kida, M.Kuwabara, et al. Spin-labeling of influenza virus hemagglutinin permits analysis of the conformational change at low pH and its inhibition by antibody. Virus Res. 1986;4:251–264.
25. J.J.Treanor, G.M.Schiff, F.G.Hayden, et al. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. J Amer Med Assoc. 2007;297:1577–1582.
26. L.A.Grohskopf, D.J.Shay, T.T.Shimabukuro, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices – United States, 2013–2014. Morbid Mortal Wk Rep. 2013;62:1–43.
27. R.Izikson, D.Laffell, A.Bock, et al. Comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ≥50 years of age. Vaccine. 2015;33:6622–6628.• Safety of Flublok in adults 50 years of age and older.
28. C.A.DiazGranados, A.J.Dunning, M.Kimmel, et al. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med. 2014;371:635–645.•• Pivotal efficacy trial of Fluzone high dose in adults 65 years of age and older.
29. Sanofi-Pasteur. Fluzone influlenza vaccine. Prescribing Information [Online]; 2015 Jun 19 [cited 2016 Jan 12]. Available from: http://www.fluzone.com/health-care-professionals/index.cfm.
30. W.E.Beyer, A.M.Palache, A.D.Osterhaus. Comparison of serology and reactogenicity between influenza subunit vaccines and whole virus or split vaccines: a review and meta-analysis of the literature. Clin Drug Investig. 1998;15:1–12.
31. L.Gustafsson, H.O.Hallander, P.Olin, et al. A controlled trial of a two-component acellular, a five-component acellular, and a whole cell pertussis vaccine. N Engl J Med. 1996;334:340–355.
32. S.Rosenthal, R.Chen, S.Hadler. The safety of acellular pertussis vaccine vs whole-cell pertussis vaccine: a post-marketing assessment. Arch Pediatr Adolesc Med. 1996;150:457–460.
33. B.E.Johansson, M.M.J.Cox. Influenza viral neuraminidase: the forgotten antigen. Expert Rev Vaccines. 2011;10:1683–1695.
34. F.Krammer, P.Palese. Influenza virus hemagglutinin stalk-based antibodies and vaccines. Curr Opin Virol. 2013;3:521–530.
35. R.Nachbagauer, A.Choi, R.Izikson, et al. Age dependence and isotype specificity of influenza virus hemagglutinin stalk-reactive antibodies in humans. MBio. 2015;6:e01996–e02015.•• Anti-stalk immunogenicity of Flublok as possible explanation for cross-antigen protection.
36. I.Schulze. Effects of glycosylation on the properties and functions of influenza virus hemagglutinin. J Infect Dis. 1997;176:S24–S28.
37. C.C.Wang, J.-R.Chen, Y.-C.Tseng, et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci USA. 2009;106:18137–18142.•• Describes the role of HA glycosylation in differences in cross-antigenic vaccine protection.
38. J.L.Schulman, M.Khakpour, E.D.Kilbourne. Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol. 1968;2:778–786.